Combinational Targeting of Prostate Carcinoma Cells and Tumors Associated Pericytes with Antibody Based Immunotherapy and Metronomic Chemotherapy
Annual rept.8 Jan 2007-7 Jan 2008
PITTSBURGH UNIV PA
Pagination or Media Count:
The hybridoma secreting the HMW-MAA-specific mAb 225.28 which is used for immuno prevention of prostate carcinoma and the hybridoma secreting the isotype matched mAb F3C25 have been tested for activity. Ascitis has been prepared and monoclonal antibodies have been purified and monitored for purity and activity. The colony of TRAMP mice has been expanded to test the efficacy of mAb 225.28 plus cyclophosphamide metronomic therapy in the inhibition of progression of prostate cancer. Sixty-four TRAMP mice have been enrolled in the combinatorial treatment schedule. Animals are being screened 2 times a week for palpable tumors.
- Medicine and Medical Research